Molecular and Clinical Advances in Anticancer Drug Resistance:
The importance of drug resistance in cancer chemotherapy cannot be over stated. The 500,000 patients who die every year from cancer in the United States have, in most cases, been treated with chemotherapy. Many of these patients responded initially to chemotherapy, but death resulted from the devel...
Gespeichert in:
| Weitere Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Boston, MA
Springer US
1991
|
| Schriftenreihe: | Cancer Treatment and Research
57 |
| Schlagworte: | |
| Online-Zugang: | DE-355 URL des Erstveröffentlichers |
| Zusammenfassung: | The importance of drug resistance in cancer chemotherapy cannot be over stated. The 500,000 patients who die every year from cancer in the United States have, in most cases, been treated with chemotherapy. Many of these patients responded initially to chemotherapy, but death resulted from the development of drug-resistant tumors. In the first volume in the series. Drug Resistance in Chemotherapy the results of comprehensive laboratory studies aimed at understanding the mechanisms for resistance to individual agents and to the development of broad cross-resistance were described. In the past 2 years there has been substantial progress in understanding the molecular biology associated with these mechanisms of drug resistance. For the first time we are starting to understand which mechanisms are playing an im portant role in human tumors, and even more importantly, clinical trials have recently been initiated in an effort to reverse specific forms of drug resistance. The purpose of this volume is to describe the new advances, both at the molecular level and in the clinic regarding mechanisms of drug resistance and potential ways this resistance can be circumvented. This volume is focused upon mechanisms of resistance associated with two major classes of anticancer drugs: alkylating agents (including cisplatin) and the natural products (e. g. , adriamycin and vinblastine). The first section of the book describes new insights into the genetic mechanisms associated with drug resistance |
| Beschreibung: | 1 Online-Ressource (XII, 308 p) |
| ISBN: | 9781461538721 |
| DOI: | 10.1007/978-1-4615-3872-1 |
Internformat
MARC
| LEADER | 00000nam a2200000zcb4500 | ||
|---|---|---|---|
| 001 | BV046146994 | ||
| 003 | DE-604 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 190905s1991 xx o|||| 00||| eng d | ||
| 020 | |a 9781461538721 |9 978-1-4615-3872-1 | ||
| 024 | 7 | |a 10.1007/978-1-4615-3872-1 |2 doi | |
| 035 | |a (ZDB-2-SME)978-1-4615-3872-1 | ||
| 035 | |a (OCoLC)1119019007 | ||
| 035 | |a (DE-599)BVBBV046146994 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 082 | 0 | |a 616.994 |2 23 | |
| 084 | |a XD 2089 |0 (DE-625)152541:12998 |2 rvk | ||
| 245 | 1 | 0 | |a Molecular and Clinical Advances in Anticancer Drug Resistance |c edited by Robert F. Ozols |
| 264 | 1 | |a Boston, MA |b Springer US |c 1991 | |
| 300 | |a 1 Online-Ressource (XII, 308 p) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a Cancer Treatment and Research |v 57 | |
| 520 | |a The importance of drug resistance in cancer chemotherapy cannot be over stated. The 500,000 patients who die every year from cancer in the United States have, in most cases, been treated with chemotherapy. Many of these patients responded initially to chemotherapy, but death resulted from the development of drug-resistant tumors. In the first volume in the series. Drug Resistance in Chemotherapy the results of comprehensive laboratory studies aimed at understanding the mechanisms for resistance to individual agents and to the development of broad cross-resistance were described. In the past 2 years there has been substantial progress in understanding the molecular biology associated with these mechanisms of drug resistance. For the first time we are starting to understand which mechanisms are playing an im portant role in human tumors, and even more importantly, clinical trials have recently been initiated in an effort to reverse specific forms of drug resistance. The purpose of this volume is to describe the new advances, both at the molecular level and in the clinic regarding mechanisms of drug resistance and potential ways this resistance can be circumvented. This volume is focused upon mechanisms of resistance associated with two major classes of anticancer drugs: alkylating agents (including cisplatin) and the natural products (e. g. , adriamycin and vinblastine). The first section of the book describes new insights into the genetic mechanisms associated with drug resistance | ||
| 650 | 4 | |a Oncology | |
| 650 | 4 | |a Pharmacology/Toxicology | |
| 650 | 4 | |a Oncology | |
| 650 | 4 | |a Toxicology | |
| 650 | 0 | 7 | |a Pharmakotherapie |0 (DE-588)4076066-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Cytostatikum |0 (DE-588)4068347-3 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Krebszelle |0 (DE-588)4128704-6 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Arzneimittelresistenz |0 (DE-588)4143180-7 |2 gnd |9 rswk-swf |
| 655 | 7 | |8 1\p |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |D s |
| 689 | 0 | 1 | |a Cytostatikum |0 (DE-588)4068347-3 |D s |
| 689 | 0 | 2 | |a Arzneimittelresistenz |0 (DE-588)4143180-7 |D s |
| 689 | 0 | |8 2\p |5 DE-604 | |
| 689 | 1 | 0 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |D s |
| 689 | 1 | 1 | |a Pharmakotherapie |0 (DE-588)4076066-2 |D s |
| 689 | 1 | |8 3\p |5 DE-604 | |
| 689 | 2 | 0 | |a Arzneimittelresistenz |0 (DE-588)4143180-7 |D s |
| 689 | 2 | 1 | |a Krebszelle |0 (DE-588)4128704-6 |D s |
| 689 | 2 | |8 4\p |5 DE-604 | |
| 700 | 1 | |a Ozols, Robert F. |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9780792312123 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781461367260 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781461538738 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-1-4615-3872-1 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 883 | 1 | |8 1\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 883 | 1 | |8 2\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 883 | 1 | |8 3\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 883 | 1 | |8 4\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 912 | |a ZDB-2-SME | ||
| 940 | 1 | |q ZDB-2-SME_1990/2004 | |
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-031527179 | |
| 966 | e | |u https://doi.org/10.1007/978-1-4615-3872-1 |l DE-355 |p ZDB-2-SME |q ZDB-2-SME_1990/2004 |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1823607507888635904 |
|---|---|
| adam_text | |
| any_adam_object | |
| author2 | Ozols, Robert F. |
| author2_role | edt |
| author2_variant | r f o rf rfo |
| author_facet | Ozols, Robert F. |
| building | Verbundindex |
| bvnumber | BV046146994 |
| classification_rvk | XD 2089 |
| collection | ZDB-2-SME |
| ctrlnum | (ZDB-2-SME)978-1-4615-3872-1 (OCoLC)1119019007 (DE-599)BVBBV046146994 |
| dewey-full | 616.994 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.994 |
| dewey-search | 616.994 |
| dewey-sort | 3616.994 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| doi_str_mv | 10.1007/978-1-4615-3872-1 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>00000nam a2200000zcb4500</leader><controlfield tag="001">BV046146994</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">190905s1991 xx o|||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781461538721</subfield><subfield code="9">978-1-4615-3872-1</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-1-4615-3872-1</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-SME)978-1-4615-3872-1</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1119019007</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV046146994</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.994</subfield><subfield code="2">23</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XD 2089</subfield><subfield code="0">(DE-625)152541:12998</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Molecular and Clinical Advances in Anticancer Drug Resistance</subfield><subfield code="c">edited by Robert F. Ozols</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Boston, MA</subfield><subfield code="b">Springer US</subfield><subfield code="c">1991</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (XII, 308 p)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Cancer Treatment and Research</subfield><subfield code="v">57</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The importance of drug resistance in cancer chemotherapy cannot be over stated. The 500,000 patients who die every year from cancer in the United States have, in most cases, been treated with chemotherapy. Many of these patients responded initially to chemotherapy, but death resulted from the development of drug-resistant tumors. In the first volume in the series. Drug Resistance in Chemotherapy the results of comprehensive laboratory studies aimed at understanding the mechanisms for resistance to individual agents and to the development of broad cross-resistance were described. In the past 2 years there has been substantial progress in understanding the molecular biology associated with these mechanisms of drug resistance. For the first time we are starting to understand which mechanisms are playing an im portant role in human tumors, and even more importantly, clinical trials have recently been initiated in an effort to reverse specific forms of drug resistance. The purpose of this volume is to describe the new advances, both at the molecular level and in the clinic regarding mechanisms of drug resistance and potential ways this resistance can be circumvented. This volume is focused upon mechanisms of resistance associated with two major classes of anticancer drugs: alkylating agents (including cisplatin) and the natural products (e. g. , adriamycin and vinblastine). The first section of the book describes new insights into the genetic mechanisms associated with drug resistance</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmacology/Toxicology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncology </subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Toxicology</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pharmakotherapie</subfield><subfield code="0">(DE-588)4076066-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Cytostatikum</subfield><subfield code="0">(DE-588)4068347-3</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Krebszelle</subfield><subfield code="0">(DE-588)4128704-6</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittelresistenz</subfield><subfield code="0">(DE-588)4143180-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="8">1\p</subfield><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Cytostatikum</subfield><subfield code="0">(DE-588)4068347-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Arzneimittelresistenz</subfield><subfield code="0">(DE-588)4143180-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="8">2\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Pharmakotherapie</subfield><subfield code="0">(DE-588)4076066-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="8">3\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="2" ind2="0"><subfield code="a">Arzneimittelresistenz</subfield><subfield code="0">(DE-588)4143180-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2="1"><subfield code="a">Krebszelle</subfield><subfield code="0">(DE-588)4128704-6</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2=" "><subfield code="8">4\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ozols, Robert F.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9780792312123</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781461367260</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781461538738</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1007/978-1-4615-3872-1</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">1\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">2\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">3\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">4\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SME</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">ZDB-2-SME_1990/2004</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-031527179</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/978-1-4615-3872-1</subfield><subfield code="l">DE-355</subfield><subfield code="p">ZDB-2-SME</subfield><subfield code="q">ZDB-2-SME_1990/2004</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| genre | 1\p (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV046146994 |
| illustrated | Not Illustrated |
| indexdate | 2025-02-09T19:00:43Z |
| institution | BVB |
| isbn | 9781461538721 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-031527179 |
| oclc_num | 1119019007 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 1 Online-Ressource (XII, 308 p) |
| psigel | ZDB-2-SME ZDB-2-SME_1990/2004 ZDB-2-SME ZDB-2-SME_1990/2004 |
| publishDate | 1991 |
| publishDateSearch | 1991 |
| publishDateSort | 1991 |
| publisher | Springer US |
| record_format | marc |
| series2 | Cancer Treatment and Research |
| spelling | Molecular and Clinical Advances in Anticancer Drug Resistance edited by Robert F. Ozols Boston, MA Springer US 1991 1 Online-Ressource (XII, 308 p) txt rdacontent c rdamedia cr rdacarrier Cancer Treatment and Research 57 The importance of drug resistance in cancer chemotherapy cannot be over stated. The 500,000 patients who die every year from cancer in the United States have, in most cases, been treated with chemotherapy. Many of these patients responded initially to chemotherapy, but death resulted from the development of drug-resistant tumors. In the first volume in the series. Drug Resistance in Chemotherapy the results of comprehensive laboratory studies aimed at understanding the mechanisms for resistance to individual agents and to the development of broad cross-resistance were described. In the past 2 years there has been substantial progress in understanding the molecular biology associated with these mechanisms of drug resistance. For the first time we are starting to understand which mechanisms are playing an im portant role in human tumors, and even more importantly, clinical trials have recently been initiated in an effort to reverse specific forms of drug resistance. The purpose of this volume is to describe the new advances, both at the molecular level and in the clinic regarding mechanisms of drug resistance and potential ways this resistance can be circumvented. This volume is focused upon mechanisms of resistance associated with two major classes of anticancer drugs: alkylating agents (including cisplatin) and the natural products (e. g. , adriamycin and vinblastine). The first section of the book describes new insights into the genetic mechanisms associated with drug resistance Oncology Pharmacology/Toxicology Oncology Toxicology Pharmakotherapie (DE-588)4076066-2 gnd rswk-swf Cytostatikum (DE-588)4068347-3 gnd rswk-swf Krebszelle (DE-588)4128704-6 gnd rswk-swf Krebs Medizin (DE-588)4073781-0 gnd rswk-swf Arzneimittelresistenz (DE-588)4143180-7 gnd rswk-swf 1\p (DE-588)4143413-4 Aufsatzsammlung gnd-content Krebs Medizin (DE-588)4073781-0 s Cytostatikum (DE-588)4068347-3 s Arzneimittelresistenz (DE-588)4143180-7 s 2\p DE-604 Pharmakotherapie (DE-588)4076066-2 s 3\p DE-604 Krebszelle (DE-588)4128704-6 s 4\p DE-604 Ozols, Robert F. edt Erscheint auch als Druck-Ausgabe 9780792312123 Erscheint auch als Druck-Ausgabe 9781461367260 Erscheint auch als Druck-Ausgabe 9781461538738 https://doi.org/10.1007/978-1-4615-3872-1 Verlag URL des Erstveröffentlichers Volltext 1\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk 2\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk 3\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk 4\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk |
| spellingShingle | Molecular and Clinical Advances in Anticancer Drug Resistance Oncology Pharmacology/Toxicology Oncology Toxicology Pharmakotherapie (DE-588)4076066-2 gnd Cytostatikum (DE-588)4068347-3 gnd Krebszelle (DE-588)4128704-6 gnd Krebs Medizin (DE-588)4073781-0 gnd Arzneimittelresistenz (DE-588)4143180-7 gnd |
| subject_GND | (DE-588)4076066-2 (DE-588)4068347-3 (DE-588)4128704-6 (DE-588)4073781-0 (DE-588)4143180-7 (DE-588)4143413-4 |
| title | Molecular and Clinical Advances in Anticancer Drug Resistance |
| title_auth | Molecular and Clinical Advances in Anticancer Drug Resistance |
| title_exact_search | Molecular and Clinical Advances in Anticancer Drug Resistance |
| title_full | Molecular and Clinical Advances in Anticancer Drug Resistance edited by Robert F. Ozols |
| title_fullStr | Molecular and Clinical Advances in Anticancer Drug Resistance edited by Robert F. Ozols |
| title_full_unstemmed | Molecular and Clinical Advances in Anticancer Drug Resistance edited by Robert F. Ozols |
| title_short | Molecular and Clinical Advances in Anticancer Drug Resistance |
| title_sort | molecular and clinical advances in anticancer drug resistance |
| topic | Oncology Pharmacology/Toxicology Oncology Toxicology Pharmakotherapie (DE-588)4076066-2 gnd Cytostatikum (DE-588)4068347-3 gnd Krebszelle (DE-588)4128704-6 gnd Krebs Medizin (DE-588)4073781-0 gnd Arzneimittelresistenz (DE-588)4143180-7 gnd |
| topic_facet | Oncology Pharmacology/Toxicology Oncology Toxicology Pharmakotherapie Cytostatikum Krebszelle Krebs Medizin Arzneimittelresistenz Aufsatzsammlung |
| url | https://doi.org/10.1007/978-1-4615-3872-1 |
| work_keys_str_mv | AT ozolsrobertf molecularandclinicaladvancesinanticancerdrugresistance |